Myo means muscle, and the term clonus implies jerk or twitching of
muscles. Myoclonic seizure is, therefore, defined as brief, shock-like
alternate contraction and relaxation of muscles. According to the World
Health Organization (WHO), around 50 million people have epilepsy
globally, making it one of the most common nervous system diseases.
Myoclonic epilepsy causes abnormal movements of body parts and increases
muscle tone. A patient suffering from myoclonic epilepsy experiences
sudden and dramatic changes in muscle tone, which lasts for a couple of
seconds. Jerks due to myoclonic epilepsy are brief, and can happen in a
cluster. It is the most common form of generalized epilepsy syndrome
that emerges in mid-to-late childhood. The condition is considered to be
more serious than general epilepsy, as anticonvulsant therapy is
ineffective in treating the syndrome.
Awareness about myoclonic epilepsy pertaining to the availability of
technologically advanced diagnostics and treatment methods among
consumers is a key factor fueling the growth of the myoclonic epilepsy
market during the forecast period. However, according to the WHO, around
80% people suffering from epilepsy live in low and middle-income
countries, with poor medical facilities. This is expected to hamper
market growth from 2018 to 2026. Research and development on the
treatment of neurological disorders presents significant opportunities
for companies in the global myoclonic epilepsy market.
The global myoclonic epilepsy market can be segmented based on
disorder type and therapy type. Based on disorder type, the global
market can be categorized into juvenile myoclonic epilepsy (Janz
syndrome) and progressive myoclonic epilepsy. Janz syndrome is
associated with the body parts such as shoulders, neck, and upper arms.
The progressive myoclonic epilepsy segment captured the largest market
share in terms of revenue in 2017, attributed to significant prevalence
and rise in awareness about the condition. Progressive myoclonic
epilepsy generally shows symptoms of both myoclonic and tonic-clonic
seizures. The segment is projected to continue to dominate the market
during the forecast period. In terms of therapy type, the global
myoclonic epilepsy market can be classified into various drugs such as
Levetiracetam, Valproate, Topiramate, Lamotrigine, Levetiracetam, and
others. Valproate accounted for the largest market share in terms of
revenue in 2017, owing to its choice as a first line therapy by
physicians for recurrent myoclonic epileptic attacks and its
broad-spectrum activity against generalized seizures. Levetiracetam is
expected to grow at a rapid pace during the forecast period, as the drug
has received regulatory approval for the treatment of juvenile
myoclonic epilepsy. Lamotrigine is projected to be the second most
prominent drug for myoclonic epilepsy owing to its wide distribution
across the globe. The others segment comprises anticonvulsant drugs such
as Topiramate, Zonisamide, and Clonazepam. Funding by public and
private players to boost R&D on neurovascular disorder treatments
and improved distribution network of the key manufacturers across the
globe are expected to augment the growth of the others segment from 2018
to 2026.
Geographically, the global myoclonic epilepsy market can be segmented
into North America, Europe, Asia Pacific, Latin America, and Middle
East & Africa. North America accounted for dominant share of the
global myoclonic epilepsy market in 2017, due to the strategic presence
of key companies in the U.S. and Canada, and favorable reimbursement
policies. Europe is expected to be the second most prominent market
during the forecast period. However, rise in prevalence of epilepsy in
low-income countries in Asia Pacific and significant growth of the
pharmaceutical industry in India and Japan are anticipated to propel the
market in Asia Pacific during the forecast period.
Major players operating in the global myoclonic epilepsy market include Novartis AG, Sanofi, GlaxoSmithKline plc, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, AstraZeneca plc, and Bayer AG.
Major players operating in the global myoclonic epilepsy market include Novartis AG, Sanofi, GlaxoSmithKline plc, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, AstraZeneca plc, and Bayer AG.
No comments:
Post a Comment